Physician profile
Charles Mills
NPI 1689659674
$7,192.63
in general payments reported to CMS, 2019-2025
32 companies · $842 in 2025
The $842 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,853 · 2020: $793 · 2021: $765 · 2022: $1,006 · 2023: $927 · 2024: $1,007 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,766.33 | 2019-2025 | |
| Amgen INC. | $1,555.99 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $751.16 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $529.63 | 2019-2024 | Benlysta |
| Pfizer INC. | $426.31 | 2019-2024 | |
| Horizon Therapeutics Plc | $406.27 | 2019-2022 | |
| Janssen Biotech, INC. | $335.13 | 2019-2023 | Tremfya |
| Lilly USA, LLC | $282.35 | 2019-2025 | Taltz |
| Novartis Pharmaceuticals Corporation | $133.16 | 2019-2022 | |
| Radius Health, INC. | $102.74 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $99.48 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $82.56 | 2023-2024 | Idacio |
| Celgene Corporation | $72.19 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.50 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $59.57 | 2025 | Purified Cortrophin Gel |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $59.49 | 2019 | |
| Genzyme Corporation | $50.22 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $46.21 | 2020 | |
| Genentech USA, INC. | $45.94 | 2020-2023 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $44.72 | 2019 | |
| Novo Nordisk INC | $44.14 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $34.83 | 2020-2021 | |
| Dexcom, INC. | $32.98 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $29.97 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $21.53 | 2023 | |
| Antares Pharma, INC. | $18.07 | 2019 | |
| Ibsa Pharma INC. | $16.97 | 2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $16.90 | 2023 | Arcalyst |
| United Therapeutics Corporation | $16.04 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.90 | 2019 | |
| Sanofi Pasteur INC. | $13.78 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.